Sofgen Pharma S.A PROCF

0.00 0.00 NaN as of 24 Sep
Market cap
$114.0M
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Mar '23 Jun '23 Sep '23 Dec '23
Revenue

+8 more TTM periods

401.74 399.37 407.38 423.75
Cost of Revenue
167.67 176.75 183.91 185.77
Gross Profit
234.07 222.62 223.47 237.98
SG&A Expenses
195.77 187.36 192.37 193.35
Operating Income
10.68 7.64 3.48 72.08
Interest Expense (Operating)
39.92 44.75 49.42 —
Non-operating Income/Expense
23.83 74.09 59.30 (26.12)
EBT
34.50 81.73 62.78 45.96
Income Tax Provision
8.20 21.56 16.99 5.62
Income after Tax
26.30 60.18 45.79 40.34
Net Income Common
26.30 60.18 45.79 40.34
EPS (Basic)
0.26 0.60 0.46 0.41
Gross Margin
58.26% 55.74% 54.85% 56.16%
EBIT Margin
2.66% 1.91% 0.85% 17.01%
EBT margin
8.59% 20.47% 15.41% 10.85%
Net Profit Margin
6.55% 15.07% 11.24% 9.52%
Free Cash Flow Margin
(5.22%) (2.36%) 7.85% 17.66%
EBITDA
27.73 24.14 20.94 90.28
EBIT
10.68 7.64 3.48 72.08
EPS (Diluted, from Cont. Ops)
0.26 0.60 0.45 0.40
EPS (Basic, Consolidated)
0.26 0.60 0.45 0.40
EPS (Basic, from Continuous Ops)
0.26 0.60 0.45 0.40
Income from Continuous Operations
26.30 60.18 45.79 40.34
Consolidated Net Income/Loss
26.30 60.18 45.79 40.34
EBITDA Margin
6.90% 6.04% 5.14% 21.30%
Operating Cash Flow Margin
3.07% 5.71% 15.82% 25.40%

Fold the line items

In millions of $ except per-share values · columns are period end dates